Navigation Links
Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
Date:9/3/2009

of nearly 600 representatives. INTUNIV is not a controlled substance and has no known potential for abuse or dependence.

"Everyday situations and challenges may be difficult for children and adolescents with ADHD as it is a disruptive disorder that includes symptoms and behaviors such as being easily distracted, always on the go, interrupting others, arguing with adults, or temper outbursts," said Frank A. Lopez, MD, a neurodevelopmental pediatrician in private practice at Children's Developmental Center in Winter Park, Florida. "In clinical trials, INTUNIV, a selective alpha-2A receptor agonist, significantly reduced ADHD symptoms across a full day as measured by parents at 6 pm, 8 pm, and 6 am the next morning. This is important because children with ADHD require symptom control at home, school, and during after school activities."

The introduction of INTUNIV is consistent with the strategy of Shire to expand and diversify its ADHD portfolio, which now consists of four ADHD treatment options of scheduled and nonscheduled medicines in the United States and two ADHD medicines available outside the United States.

Additional information about INTUNIV and Full Prescribing Information are available at http://www.intuniv.com.

INTUNIV Demonstrated Significant Reduction in ADHD Symptoms

The efficacy of INTUNIV in the treatment of ADHD was established in two, similarly designed, placebo-controlled clinical trials in children and adolescents aged 6 to 17 years who met Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV(R)) criteria for ADHD. Statistically significant improvements were reported by investigators, parents, and teachers.

The first pivotal trial was a phase III, double-blind, parallel-group trial, in which investigators randomized 345 children aged 6 to 17 years to eith
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... und TÜBINGEN, Deutschland, 5. März 2015 ... Stiftung und das deutsche biopharmazeutische Unternehmen CureVac ... Millionen Euro (52 Millionen US-Dollar) in CureVac ... der medizinisch angewandten Messenger-RNA (mRNA). Auf Basis ... zur Behandlung von Krankheiten und zum Schutz ...
(Date:3/5/2015)... 5, 2015 Bayer HealthCare announced today that ... Cancer Foundation of the American Society of Clinical Oncology ... technology platform designed to unlock vast quantities of information ... "Bayer is proud to join ASCO and ... Big Data to help people whose lives have been ...
(Date:3/5/2015)... March 5, 2015  Medical Diagnostic Laboratories, L.L.C., ... high complexity, state-of-the-art, automated DNA-based molecular analyses, announces ... (HPV) testing which utilizes cutting edge technology, including ... year, approximately 12,000 women are diagnosed with cervical ... . Genital Human Papillomaviruses (HPV) are a group ...
Breaking Medicine Technology:Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 2Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 3Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3
... Chimerix, Inc., a biotechnology company developing orally-available antiviral ... the Board and Chief Scientific Officer, will participate on ... Therapeutics Conference on July 22nd, 2011, 10:30 am ET. ... Club in Washington, D.C. on July 20-22, 2011, and ...
... July 20, 2011 Concentric Medical, Inc., the global ... patients, today announced the launch of the expanded family ... the V 2.0 Soft and V 3.0 Soft, through ... Merci Retrievers® are now approved and reimbursed in Japan. ...
Cached Medicine Technology:Chimerix to Present at Infocast's 9th Annual Biodefense Vaccines & Therapeutics Conference 2Chimerix to Present at Infocast's 9th Annual Biodefense Vaccines & Therapeutics Conference 3Concentric Medical Launches Full Family of Merci Retrievers® in Japan 2Concentric Medical Launches Full Family of Merci Retrievers® in Japan 3
(Date:3/6/2015)... 06, 2015 FCPX developers have ... Film Studios. , “Pro3rd Hue is a lower 3rd pack ... of Pixel Film Studios. “Blurring the line between professional and ... Hue is a set of 30 customizable lower third presets ... Pro3rd Hue, FCPX users can complement any design with a ...
(Date:3/6/2015)... 2015 Fluid Running® Owner, Jennifer Conroyd, ... the Fluid Running® method 3 years ago ... marathon. She hit upon the trifecta of combining matched-bpm ... a maximum-resistance, deep water running technique. She not only ... water running workout that made the experience both enjoyable ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 From Oct. 5-10, ... 2015 Textile Sustainability Conference . These dates include the following ... for all Attendees , October 6: Conference Day ... October 7: Conference Day 2, ending with Local Entertainment ... Cotton Round Table and other Materials Meetings , ...
(Date:3/5/2015)... 05, 2015 This week, ... in low-cost laminate flooring products, initiating widespread concern ... eco-friendly building materials made primarily from bamboo, stands ... all their flooring products for volatile organic compounds ... Benchmark International (BMH). Results from formaldehyde emissions ...
(Date:3/5/2015)... March 05, 2015 Testosterone lawsuits ( ... suffered heart attacks, strokes and other serious cardiovascular events ... continue to move forward in the federal multidistrict litigation ... Illinois. According to a Case Management Order issued on ... the use of master pleadings in the proceeding. Among ...
Breaking Medicine News(10 mins):Health News:A New Plugin Entitled Pro3rd Hue was Released Today from Pixel Film Studios Exclusively for FCPX 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 3Health News:Textile Exchange Announces the 2015 Textile Sustainability Conference Dates 2Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4
... Filings, with Additional Applications ... ... Group,Inc. (Amex: QGP, QGP.WSA, QGP.WSB) (http://www.QuantumMD.com ) announced today that,it ... Patent and Trademark Office, adding to the five applications,filed and announced ...
... reliability, improves information flow, facilitates documentation and, compliance, ... ... outcomes., ... the release of an enhanced NaviCare(R) WatchChild(R),solution, following receipt of ...
... IDEXX,Laboratories, Inc. (Nasdaq: IDXX ), has scheduled ... Friday, April 25, at approximately 7:00,a.m. (eastern). The Company ... (eastern) on that day., Individuals can access a ... the IDEXX Web site, http://www.idexx.com . An archived ...
... ,Washington University School of Medicine in St. Louis ... have announced a research,collaboration that aims to develop ... disease., The major focus of the alliance ... spinal fluid, that physicians can use to diagnose,Alzheimer,s ...
... to Twin Cities, consumers, the bi-monthly magazine,published in partnership with the ... and edited by the most experienced health ... journalists in the country, ... will soon have a unique health and wellness resource available to,them: ...
... magnets to enable ,armed, human cells to target ... the Biotechnology and Biological Sciences Research Council (BBSRC). ... journal, Gene Therapy, shows that inserting these nanomagnets ... in many more cells successfully reaching and invading ...
Cached Medicine News:Health News:The Quantum Group Files Four Additional Patents 2Health News:The Quantum Group Files Four Additional Patents 3Health News:The Quantum Group Files Four Additional Patents 4Health News:Hill-Rom's NaviCare(R) WatchChild(R) Solution Provides Enhanced Information Technology Solutions for Obstetrical Care 2Health News:IDEXX Laboratories to Release 2008 First Quarter Financial Results 2Health News:Washington University in St. Louis and AstraZeneca Announce Alzheimer's Research Collaboration 2Health News:Washington University in St. Louis and AstraZeneca Announce Alzheimer's Research Collaboration 3Health News:Washington University in St. Louis and AstraZeneca Announce Alzheimer's Research Collaboration 4Health News:The Best Things in Life Are ... In Better Health & Living(R), A Free, Premium Magazine Launching April 26 in the Twin Cities 2Health News:The Best Things in Life Are ... In Better Health & Living(R), A Free, Premium Magazine Launching April 26 in the Twin Cities 3Health News:Tiny magnets offer breakthrough in gene therapy for cancer 2
... The Ray TFC Unite Device is the anterior ... Ray TFC Unite device features the same 70% ... offered by fenestrations is paramount in the formation ... Ray TFC Unite system promotes load sharing between ...
... Ray Threaded Fusion Cage is a proven interbody* ... IDE). This device is a hollow threaded cylinder ... this contact the device promotes spinal fusion by ... Ray TFC is indicated for use with autogenous ...
... System has added a significant layer of ... It utilizes innovative technologies developed by Gen-Probe ... acid amplification technique called Transcription-Mediated Amplification (TMA).,The ... presence of HIV-1 and HCV in blood ...
... Test (Reveal Test) is MedMiras flagship rapid ... human serum or plasma against HIV-1 that ... to HIV infection. The Reveal Test is ... and is comprised of a single-use test ...
Medicine Products: